Literature DB >> 9721088

A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer.

G N Hortobagyi1, M C Hung, G Lopez-Berestein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9721088     DOI： 10.1089/hum.1998.9.12-1775

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  5 in total

1.  FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization.

Authors:  Jen-Liang Su; Xiaoyun Cheng; Hirohito Yamaguchi; Yi-Wen Chang; Chao-Feng Hou; Dung-Fang Lee; How-Wen Ko; Kuo-Tai Hua; Ying-Nai Wang; Michael Hsiao; Poshen B Chen; Jung-Mao Hsu; Robert C Bast; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Cancer Res       Date:  2011-09-12       Impact factor: 12.701

2.  Designing a HER2/neu promoter to drive alpha1,3galactosyltransferase expression for targeted anti-alphaGal antibody-mediated tumor cell killing.

Authors:  Marion Lanteri; Laurence Ollier; Valérie Giordanengo; Jean-Claude Lefebvre
Journal:  Breast Cancer Res       Date:  2005-05-03       Impact factor: 6.466

Review 3.  Gene therapy for carcinoma of the breast: Genetic ablation strategies.

Authors:  D T Curiel
Journal:  Breast Cancer Res       Date:  1999-12-17       Impact factor: 6.466

Review 4.  Gene therapy for carcinoma of the breast: Pro-apoptotic gene therapy.

Authors:  J Gómez-Navarro; W Arafat; J Xiang
Journal:  Breast Cancer Res       Date:  1999-12-17       Impact factor: 6.466

5.  De-acetylation and degradation of HSPA5 is critical for E1A metastasis suppression in breast cancer cells.

Authors:  Yi-Wen Chang; Hsin-An Chen; Chi-Feng Tseng; Chih-Chen Hong; Jui-Ti Ma; Mien-Chie Hung; Chih-Hsiung Wu; Ming-Te Huang; Jen-Liang Su
Journal:  Oncotarget       Date:  2014-11-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.